Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387206777> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4387206777 endingPage "e412" @default.
- W4387206777 startingPage "e412" @default.
- W4387206777 abstract "Stereotactic ablative body radiotherapy (SABR) is one of the treatment options for metastatic renal cell carcinoma (mRCC) but is limited by a lack of data to evaluate targeted therapy plus immunotherapy concurrently with high-dose SABR to multiple sites. We evaluated the safety and disease control for mRCC patients who concurrently received the above tri-modality treatment.Patients were treated with SABR (40-70 Gy/5-10 fractions) for small lesions or partial-SABR (tumor center boosted with 6-8 Gy/3-5 fractions with 50-60 Gy/20-25 fractions to the whole tumor volume) for bulky tumors or tumors adjacent to critical organs. When SABR/partial-SABR was not feasible, a moderate fractionated radiotherapy plan, usually 60Gy/20 fractions were applied. of Targeted therapy plus immunotherapy (PD-1 inhibitor) was not interrupted during or after radiotherapy (RT). Adverse events (AEs) were evaluated. Disease control rate (DCR), objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) were calculated. The PFS1 was defined as the first progression since the start of RT. The PFS2 was defined as the second progression after the second RT course, if new metastases occurred after first RT were all re-irradiated, and the systemic therapy was not changed. The Kaplan-Meier method was used for time-to-event endpoints.A total of 51 patients, with a median age of 57 yr, were enrolled. The median follow-up was 12 months. There were 75% of patients with intermediate-risk and 18% with favorable-risk disease. 61% of the patients were oligometastatic. 71% had clear cell renal cancer. There were 241 metastases while 161 (67%) were irradiated. 80% of the lesions received SABRP/partial SABR. 1 patient with 14 lesions irradiated received proton therapy. All the surviving patients are continuing using targeted therapy while 81% patients complete at least 1-year PD-1 therapy. 10 patients (20%) had grade 3 drug-related AEs: pneumonitis (n = 2), elevated alanine transaminase (n = 4), myositis (n = 1), hand-foot syndrome myositis (n = 1), enteritis (n = 1), fatigue (n = 1). There were 1 grade 4 AEs of upper gastrointestinal bleeding. No grade 3-5 RT-related AEs was found. ORR and DCR for irradiated lesion were 51% and 98%. Median OS and PFS2 was not reached. Median PFS1 was 14(6-22) months. Estimated 1- and 2-yr OS, PFS1 and PFS2 were 90% and 90%, 56% and 38%, 74% and 51% respectively. Univariate analysis showed that an PFS1 benefit was found in patients who received radiation before systemic therapy failure (p = 0.038).We investigated the high-dose RT in combination of concurrent targeted and immunotherapy in patients with metastatic RCC. We found that this treatment regimen was well tolerated, with good cancer control. Early use of high-dose RT to multi-lesions may improve PFS. Partial-SABR for bulky lesions close to critical organs could be safely and effectively applied under certain circumstances. These encouraging findings warrant further investigation." @default.
- W4387206777 created "2023-09-30" @default.
- W4387206777 creator A5003656645 @default.
- W4387206777 creator A5007367240 @default.
- W4387206777 creator A5016471078 @default.
- W4387206777 creator A5019158636 @default.
- W4387206777 creator A5024765287 @default.
- W4387206777 creator A5027319465 @default.
- W4387206777 creator A5036045996 @default.
- W4387206777 creator A5043701861 @default.
- W4387206777 creator A5046722752 @default.
- W4387206777 date "2023-10-01" @default.
- W4387206777 modified "2023-10-04" @default.
- W4387206777 title "Outcomes of Targeted Therapy Plus Immunotherapy and High-Dose Stereotactic Ablative Body Radiotherapy (SABR) for Metastatic Renal Cell Cancer Patients" @default.
- W4387206777 doi "https://doi.org/10.1016/j.ijrobp.2023.06.1558" @default.
- W4387206777 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37785365" @default.
- W4387206777 hasPublicationYear "2023" @default.
- W4387206777 type Work @default.
- W4387206777 citedByCount "0" @default.
- W4387206777 crossrefType "journal-article" @default.
- W4387206777 hasAuthorship W4387206777A5003656645 @default.
- W4387206777 hasAuthorship W4387206777A5007367240 @default.
- W4387206777 hasAuthorship W4387206777A5016471078 @default.
- W4387206777 hasAuthorship W4387206777A5019158636 @default.
- W4387206777 hasAuthorship W4387206777A5024765287 @default.
- W4387206777 hasAuthorship W4387206777A5027319465 @default.
- W4387206777 hasAuthorship W4387206777A5036045996 @default.
- W4387206777 hasAuthorship W4387206777A5043701861 @default.
- W4387206777 hasAuthorship W4387206777A5046722752 @default.
- W4387206777 hasConcept C106159729 @default.
- W4387206777 hasConcept C121608353 @default.
- W4387206777 hasConcept C126322002 @default.
- W4387206777 hasConcept C143998085 @default.
- W4387206777 hasConcept C162324750 @default.
- W4387206777 hasConcept C187625094 @default.
- W4387206777 hasConcept C19617505 @default.
- W4387206777 hasConcept C197934379 @default.
- W4387206777 hasConcept C2777472916 @default.
- W4387206777 hasConcept C2777714996 @default.
- W4387206777 hasConcept C2779524853 @default.
- W4387206777 hasConcept C509974204 @default.
- W4387206777 hasConcept C71924100 @default.
- W4387206777 hasConcept C85393063 @default.
- W4387206777 hasConcept C91602232 @default.
- W4387206777 hasConceptScore W4387206777C106159729 @default.
- W4387206777 hasConceptScore W4387206777C121608353 @default.
- W4387206777 hasConceptScore W4387206777C126322002 @default.
- W4387206777 hasConceptScore W4387206777C143998085 @default.
- W4387206777 hasConceptScore W4387206777C162324750 @default.
- W4387206777 hasConceptScore W4387206777C187625094 @default.
- W4387206777 hasConceptScore W4387206777C19617505 @default.
- W4387206777 hasConceptScore W4387206777C197934379 @default.
- W4387206777 hasConceptScore W4387206777C2777472916 @default.
- W4387206777 hasConceptScore W4387206777C2777714996 @default.
- W4387206777 hasConceptScore W4387206777C2779524853 @default.
- W4387206777 hasConceptScore W4387206777C509974204 @default.
- W4387206777 hasConceptScore W4387206777C71924100 @default.
- W4387206777 hasConceptScore W4387206777C85393063 @default.
- W4387206777 hasConceptScore W4387206777C91602232 @default.
- W4387206777 hasIssue "2" @default.
- W4387206777 hasLocation W43872067771 @default.
- W4387206777 hasLocation W43872067772 @default.
- W4387206777 hasOpenAccess W4387206777 @default.
- W4387206777 hasPrimaryLocation W43872067771 @default.
- W4387206777 hasRelatedWork W2196797460 @default.
- W4387206777 hasRelatedWork W2519254806 @default.
- W4387206777 hasRelatedWork W2972869244 @default.
- W4387206777 hasRelatedWork W2982108766 @default.
- W4387206777 hasRelatedWork W3029134866 @default.
- W4387206777 hasRelatedWork W3094453331 @default.
- W4387206777 hasRelatedWork W3112607697 @default.
- W4387206777 hasRelatedWork W4205678797 @default.
- W4387206777 hasRelatedWork W4292552698 @default.
- W4387206777 hasRelatedWork W2777338963 @default.
- W4387206777 hasVolume "117" @default.
- W4387206777 isParatext "false" @default.
- W4387206777 isRetracted "false" @default.
- W4387206777 workType "article" @default.